Enzyme phosphodiesterase 5 (PDE5), one of the major cGMP negative regulators, was found to be highly expressed in multiple myeloma patients as compared to healthy donors, suggesting that PDE5 could be a target for a possible combinatorial therapy with 5 μM EGCG [74]. This evidence concerns the gene PDE5A and plasma cell myeloma.